*   In December 2023, we entered into an exclusive sales distribution agreement with Grand Life Sciences (Shandong) Co., Ltd., granting Yuanda Life Sciences the exclusive rights to promote and market Zepuning® in Mainland China, Hong Kong, Macau, and the Taiwan region (collectively referred to as "Greater China").

*   In June 2025, we entered into an exclusive sales distribution agreement with ATSA, a Swiss affiliate of Merck, granting it the exclusive rights to promote and market Zesuning® in Mainland China.

*   In December 2025, we entered into a strategic collaboration and option-to-license agreement with AbbVie Group Holding Company (registered in Bermuda) ("AbbVie") for the global development and commercialization of ZG006 (Alveltamig). Under the agreement, AbbVie obtained exclusive rights to develop and commercialize ZG006 (Alveltamig) outside Greater China (includes Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region), while Zelgen retained the development and commercialization rights for ZG006 within Greater China.